News & Media / Newsroom
"Looking after people so as they can live up to one hundred years" are the words of Marino Golinelli who today also exceeds this goal and reaches another: 101!
Chief Executive Officer of Alfasigma, Pier Vincenzo Colli, has decided to leave the company by the end of October; at the same time, the company announces that Francesco Balestrieri will be appointed Chief Executive Officer. This change will be effective starting from 1° November 2021.
Over 17 million EUR invested in LABIO 4.0 Marino Golinelli
Two days dedicated to Open Innovation and the promotion of young talent with a group of Spanish students winning Alfathon Day
Alfasigma, Utopia SIS, David Chiossone Institute and Club2021 will invest 6 million euros with two rounds of seeding to initiate the final clinical phase of experimentation of this possible solution for neurodegenerative diseases of the retina.
The project will focus on the development of an injectable and biocompatible device, called 'liquid retina', which would allow the partial recovery of sight of people suffering from partial blindness due to retinal degenerative diseases.
In the last months different Alfasigma new websites were released: Global, Russia, Portugal, Tunisia, Czech and Slovak Republics.
The new corporate Alfasigma websites meet most modern technical requirements and have a striking design and a very user friendly interface.
The agreement covers the countries of the European Union, the European Economic Area, the United Kingdom, Ukraine, Russia and the CIS.
Bentracimab is a human monoclonal antibody fragment to counteract the antiplatelet effects of ticagrelor.
After the recent acquisition of Lumeblue®, Alfasigma's pipeline is enriched with a biotechnological drug.
Corporate Communication & Institutional Relations
Staff
[email protected] +39.051.6489.511Press Office
[email protected]You’re entering Alfasigma global website
I agree